Short-term treatment of mild to moderate atopic eczema
(including flares) when topical corticosteroids cannot be
used (initiated by a specialist)
▶TO THE SKIN
▶Adult: Apply twice daily until symptoms resolve (stop
treatment if eczema worsens or no response after
6 weeks)
Short-term treatment of facial, flexural, or genital
psoriasis in patients unresponsive to, or intolerant of
other topical therapy (initiated by a specialist)
▶TO THE SKIN
▶Adult: Apply twice daily until symptoms resolve
(maximum duration of treatment 4 weeks)
l UNLICENSED USE Pimecrolimus is not licensed for short-
term treatment of facial, flexural, or genital psoriasis in
patients unresponsive to, or intolerant of other topical
therapy.
PDF page 1343
Application to malignant or
potentially malignant skin lesions. application under
occlusion. congenital epidermal barrier defects. contact
with eyes. contact with mucous membranes. generalised
erythroderma. immunodeficiency. infection at treatment
site
PDF page 1343
Alcohol consumption (risk of facial flushing
and skin irritation). avoid other topical treatments except
emollients at treatment site. UV light (avoid excessive
exposure to sunlight and sunlamps)
PDF page 1343
NICE decisions
▶Tacrolimus and pimecrolimus for atopic eczema (August
2004) NICE TA82
Topical pimecrolimus is an option for atopic eczema not
controlled by maximal topical corticosteroid treatment or
if there is a risk of important corticosteroid side-effects
(particularly skin atrophy).
Topical pimecrolimus is recommended for moderate
atopic eczema on the face and neck of children aged
2–16 years. Pimecrolimus should be used within its
licensed indications.
www.nice.org.uk/TA82
PDF page 1343
